Insmed Inc (INSM)
Insmed Inc (INSM) carries a ŷRobot AI score of 20 out of 100. The model's fair value estimate is $97.34, 19.7% below the last close of $121.16. The chart signal reads Hold.
| Metric | INSM |
|---|---|
| AI score | 20 / 100 |
| Chart signal | Hold |
| Fair value estimate | $97.34 |
| Upside to fair value | -19.7% |
| Previous close | $121.16 |
| P/E | -27.22 |
| Price / sales | 21.42 |
| Market cap | $26.49B |
| EPS | -4.10 |
| Revenue growth | 30.0% |
| 1-year price change | -23.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about INSM
Is INSM overvalued or undervalued right now?
As of Oct 30, 2026, ŷRobot's fair-value model estimates Insmed Inc (INSM) at $97.34 against a last close of $121.16, implying 19.7% downside to the model's estimate.
Is INSM's chart signal bullish or bearish?
The chart-signal model classifies INSM as Neutral as of Nov 13, 2026, with a signal score of -0.04 on a -1 to 1 scale.
What is INSM's ŷRobot AI score?
INSM scores 20 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is INSM stock expensive on P/E and P/S?
INSM trades at -27.2 times earnings and 21.4 times sales as of Nov 13, 2026.
What does INSM's seasonal forecast show?
ŷRobot's seasonal forecast curve for INSM reads +2.6% at 30 days, -25.4% at 90 days, and -23.2% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is INSM growing?
Insmed Inc's revenue growth is +30.0% and free-cash-flow growth is -42.4% on the latest reported figures.
INSM chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.